Log In
BCIQ
Print this Print this
 

HER2/neu peptide vaccine (TPIV100)

  Manage Alerts
Collapse Summary General Information
Company Mayo Clinic
DescriptionMulti-epitope vaccine using epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2; neu) class II antigens
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationBreast cancer
Indication DetailsTreat previously treated HER2-positive breast cancer
Regulatory Designation
PartnerTapImmune Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/07/2010

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today